SPA70 [CAS 931314-31-7]

SPA70 is an orally available, selective, competitive antagonist of the human pregnane X receptor (hPXR) (IC50=540 nM), which blocks the hPXR nuclear receptor signaling pathway and its mediated transcriptional activation of drug metabolizing enzymes (e.g., CYP3A4, MDR1) . SPA70 exhibits low toxicity in both in vitro and in vivo models and can be used to study hPXR-mediated cancer drug resistance and liver injury[1][2][3].

[931314-31-7]

C21H25N3O4S

415.51

CC1=C(S(=O)(C2=CC=C(C(C)(C)C)C=C2)=O)N=NN1C3=CC(OC)=CC=C3OC

Pregnane X Receptor (PXR)

99

DMSO : 40 mg/mL (ultrasonic; warming)

-20°C, 3 years (Powder)

Blue Ice